Clofarabine

氯法拉滨

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameClofarabine
Drug Alias NameClofarabinum克罗拉滨clofarabina氯伐拉滨氯法拉宾 +[14] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA polymerase alpha subunit inhibitors
TargetsDNA polymerase alpha subunitRibonucleotide reductase
Therapy Area/IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaLymphoproliferative Disorders +[27] 
Global Approved IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryUnited States
Original Approved Date2004/12/28
Country/TerritoryCanadaUnited StatesNetherlands +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteHefei Yifan Biological Pharmaceutical Co LtdSanofi +[5] 
Inactive CompaniesUtah State UniversityRoswell Park Cancer InstituteUniversity Of Rochester +[16] 
Active IndicationsAngioimmunoblastic T-cell LymphomaHistiocytosis, Langerhans-CellWaldenstrom Macroglobulinemia +[12] 
Inactive IndicationsSolid tumoursLymphoproliferative DisordersMyelodysplastic Syndromes +[15] 

Other Information

ATC CodeL01BB06
Related LinksWikipediaDrugBankKEGG